Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > AstraZeneca's ADC disappoints - on severe adverse events
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5566)
•••
Comment by Noteableon Apr 09, 2024 10:42am
116 Views
Post# 35978942

RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsApril 09, 2024 - AACR24 -  An AACR poster on Vincerx's VIP236, a small-molecule drug conjugate that targets αvβ3 and is the company’s most advanced asset, has revealed zero objective responses among 15 patients, prompting a 70% share price collapse in Vincerx this morning. 

The AACR poster concerned a phase 1 study, which enrolled patients with solid tumours not preselected for αvβ3 expression. Vincerx claimed that it would have been difficult to biopsy some solid tumours, but said that αvβ3 was very commonly expressed.

If this is indeed the case then VIP236 doesn’t appear to work particularly well. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities